论文部分内容阅读
目的分析血清糖链抗原153(carbohydrate antigen 153,CA153)与人附睾分泌蛋白4(human sapiens epididymis specific protein 4,HE4)在宫颈癌患者血清中的表达及临床诊断价值。方法采用回顾分析法研究2008年12月—2012年12月间的57例宫颈癌和59例宫颈良性肿瘤患者的临床资料,对两组患者阳性表达情况进行对比分析。计数资料采用χ2检验,计量资料采用t检验,P<0.05为差异有统计学意义。结果宫颈癌组患者CA153和HE4平均值[(96.24±22.46)U/ml、(310.17±52.55)pmol/L]均大于宫颈良性肿瘤组[(21.22±7.31)U/ml、(38.52±8.49)pmol/L],宫颈癌患者血清CA153和HE4阳性率分别为61.40%和77.19%,显著高于宫颈良性肿瘤组患者,差异均有统计学意义(均P<0.05)。CA153和HE4检测平均值和阳性率随着宫颈癌程度加重而升高。宫颈癌的临床病理学类型主要以鳞状细胞浸润癌(鳞癌)(78.95%)为主,临床分期各期患者人数比较均一。结论联合应用检测CA153和HE4能够有效提高早期诊断宫颈癌的准确度,具有临床价值。
Objective To analyze the expression of serum carbohydrate antigen 153 (CA153) and human sapiens epididymis specific protein 4 (HE4) in the serum of patients with cervical cancer and its clinical value. Methods The clinical data of 57 cases of cervical cancer and 59 cases of benign cervical cancer from December 2008 to December 2012 were retrospectively analyzed. The positive expression of the two groups of patients was compared. Count data using χ2 test, measurement data using t test, P <0.05 for the difference was statistically significant. Results The average value of CA153 and HE4 in cervical cancer group was significantly higher than that in benign tumor group [(21.22 ± 7.31) U / ml [(96.24 ± 22.46) U / ml, (310.17 ± 52.55) pmol / pmol / L]. The positive rates of serum CA153 and HE4 in patients with cervical cancer were 61.40% and 77.19%, respectively, which were significantly higher than those in benign cervical cancer patients (all P <0.05). The average value of CA153 and HE4 detection and positive rate increased with the degree of cervical cancer. The clinicopathological types of cervical cancer mainly squamous cell carcinoma (squamous cell carcinoma) (78.95%), the number of patients in all stages of clinical staging is relatively uniform. Conclusion Combined detection of CA153 and HE4 can effectively improve the accuracy of early diagnosis of cervical cancer, and has clinical value.